CpG island hypermethylation-associated silencing of non-coding RNAs transcribed from ultraconserved regions in human cancer.
Although only 1.5% of the human genome appears to code for proteins, much effort in cancer research has been devoted to this minimal fraction of our DNA. However, the last few years have witnessed the realization that a large class of non-coding RNAs (ncRNAs), named microRNAs, contribute to cancer development and progression by acting as oncogenes or tumor suppressor genes. Recent studies have also shown that epigenetic silencing of microRNAs with tumor suppressor features by CpG island hypermethylation is a common hallmark of human tumors. Thus, we wondered whether there were other ncRNAs undergoing aberrant DNA methylation-associated silencing in transformed cells. We focused on the transcribed-ultraconserved regions (T-UCRs), a subset of DNA sequences that are absolutely conserved between orthologous regions of the human, rat and mouse genomes and that are located in both intra- and intergenic regions. We used a pharmacological and genomic approach to reveal the possible existence of an aberrant epigenetic silencing pattern of T-UCRs by treating cancer cells with a DNA-demethylating agent followed by hybridization to an expression microarray containing these sequences. We observed that DNA hypomethylation induces release of T-UCR silencing in cancer cells. Among the T-UCRs that were reactivated upon drug treatment, Uc.160+, Uc283+A and Uc.346+ were found to undergo specific CpG island hypermethylation-associated silencing in cancer cells compared with normal tissues. The analysis of a large set of primary human tumors (n=283) demonstrated that hypermethylation of the described T-UCR CpG islands was a common event among the various tumor types. Our finding that, in addition to microRNAs, another class of ncRNAs (T-UCRs) undergoes DNA methylation-associated inactivation in transformed cells supports a model in which epigenetic and genetic alterations in coding and non-coding sequences cooperate in human tumorigenesis.
Lujambio
A
A
Cancer Epigenetics and Biology Program (PEBC), Bellvitge Biomedical Research Institute (IDIBELL), 08907L'Hospitalet, Barcelona, Spain.
Portela
A
A
Liz
J
J
Melo
S A
SA
Rossi
S
S
Spizzo
R
R
Croce
C M
CM
Calin
G A
GA
Esteller
M
M
D001483:Base Sequence; D045744:Cell Line, Tumor; D017124:Conserved Sequence; D018899:CpG Islands; D019175:DNA Methylation; D004273:DNA, Neoplasm / Q000737:chemistry*; D020868:Gene Silencing; D016147:Genes, Tumor Suppressor; D006801:Humans; D009369:Neoplasms / Q000235:genetics*; D022661:RNA, Untranslated / Q000235:genetics*
D004273:DNA, Neoplasm; D022661:RNA, Untranslated
Cancer Cell. 2007 Nov;12(5):407-9
17996642
Nat Rev Genet. 2008 Jan;9(1):15-26
18059368
Nat Rev Genet. 2004 Jul;5(7):522-31
15211354
Nature. 2005 Jun 9;435(7043):834-8
15944708
Nat Genet. 2009 Mar;41(3):365-70
19219043
In Silico Biol. 2003;3(3):235-40
12954087
Cell. 2006 Sep 22;126(6):1203-17
16990141
PLoS Comput Biol. 2007 Mar 9;3(3):e37
17352530
Genes Dev. 2006 Aug 15;20(16):2202-7
16882971
Proc Natl Acad Sci U S A. 1998 Jun 9;95(12):6870-5
9618505
Nature. 2006 May 4;441(7089):87-90
16625209
PLoS Genet. 2007 Sep;3(9):1709-23
17892325
Proc Natl Acad Sci U S A. 2004 Aug 10;101(32):11755-60
15284443
Cancer Biol Ther. 2007 Aug;6(8):1284-8
17660710
Cancer Res. 2008 Jun 1;68(11):4123-32
18519671
Curr Opin Oncol. 2010 Jan;22(1):35-45
19907325
Proc Natl Acad Sci U S A. 2006 Jun 13;103(24):9136-41
16754881
Nature. 2002 Apr 4;416(6880):552-6
11932749
Cancer Res. 2009 Dec 1;69(23):9038-46
19887623
Proc Natl Acad Sci U S A. 2004 Mar 2;101(9):2999-3004
14973191
Nature. 2006 Nov 23;444(7118):499-502
17086198
Science. 2009 Aug 21;325(5943):965
19556464
Cancer Cell. 2007 Sep;12(3):215-29
17785203
N Engl J Med. 2008 Dec 18;359(25):2641-50
19092150
Nature. 2007 Apr 19;446(7138):926-9
17361132
Science. 2007 Aug 17;317(5840):915
17702936
N Engl J Med. 2008 Mar 13;358(11):1148-59
18337604
Nat Genet. 2007 May;39(5):582-3
17460676
Science. 2004 May 28;304(5675):1321-5
15131266
Cell Cycle. 2005 Sep;4(9):1179-84
16096373
Proc Natl Acad Sci U S A. 2006 Feb 14;103(7):2257-61
16461460
Nat Rev Cancer. 2006 Apr;6(4):259-69
16557279
Mamm Genome. 2008 Aug;19(7-8):526-40
18636290
Science. 2003 Oct 17;302(5644):413
14563999
Cell Cycle. 2009 Feb 1;8(3):377-82
19177007
Bioessays. 2003 Oct;25(10):930-9
14505360
Cell. 2007 Feb 23;128(4):683-92
17320506
Cell. 2009 May 1;137(3):586-586.e1
19410551
EMBO J. 2003 Dec 1;22(23):6335-45
14633992
Cancer Res. 2002 Nov 15;62(22):6456-61
12438235
FEBS Lett. 2007 May 1;581(9):1805-10
17428475
Nature. 2004 Sep 16;431(7006):350-5
15372042
Proc Natl Acad Sci U S A. 2007 Nov 6;104(45):17719-24
17965236
Methods. 2001 Dec;25(4):402-8
11846609
Mol Cell. 2009 Aug 28;35(4):467-78
19716791
Oncogene. 2009 Nov 26;28(47):4212-24
19734945
Nat Genet. 2008 Jan;40(1):43-50
18066065
Nature. 2004 Oct 21;431(7011):931-45
15496913
Cancer Cell. 2006 Jun;9(6):435-43
16766263
Cancer Cell. 2007 Nov;12(5):432-44
17996647
RNA. 2008 May;14(5):872-7
18367714
Proc Natl Acad Sci U S A. 2008 Sep 9;105(36):13556-61
18768788
Nat Rev Genet. 2007 Apr;8(4):286-98
17339880
Cancer Res. 2007 Feb 15;67(4):1424-9
17308079
Cancer Res. 2008 Jul 15;68(14):5753-9
18632628
Cell. 2004 Jan 23;116(2):281-97
14744438
Cell Cycle. 2007 Jun 15;6(12):1455-9
17581274
Nat Rev Cancer. 2006 Nov;6(11):857-66
17060945
Carcinogenesis. 2008 Jun;29(6):1087-91
18495658
Proc Natl Acad Sci U S A. 2004 Jun 29;101(26):9740-4
15210942